Versa Vascular, a medical device company focused on tricuspid valve disease, has announced a significant leadership change and a substantial capital infusion. The company appointed Bill Shields, a veteran of the structural heart industry, as its new Chief Executive Officer. This appointment coincides with a $15 million expansion to its Series C financing, bringing the total round to $42 million.
New Leadership with Deep Industry Expertise
Bill Shields assumes the role of CEO, succeeding David Hovda, who is retiring but will continue as a company advisor. Shields brings extensive experience from his 15-year tenure at Medtronic’s structural heart franchise. Most recently, he served as Vice President and General Manager of its Transcatheter Mitral and Tricuspid Therapies division.
His background includes seven years leading product development and multiple clinical studies, along with eight years in marketing for transcatheter valve programs. Before his time at Medtronic, Shields was a senior engineer at Stryker, developing new orthopedic devices. He holds a mechanical engineering degree from Dartmouth and an MBA from Northwestern University’s Kellogg School of Management.
Fueling Clinical Trials and Product Development
The company also secured a $15 million extension to its Series C funding round, elevating the total committed capital for this financing stage to $42 million. This fresh investment signals strong continued confidence from its backers. The additional capital is earmarked for key strategic initiatives to advance its core technology.
These funds will primarily support the completion of the ongoing first-in-human clinical study of its novel AdapTR transcatheter tricuspid repair device. Furthermore, the financing will enable the initiation of a U.S. Early Feasibility Study. The capital will also be used for further product development and optimization to refine the innovative therapy.
Investor Confidence and Market Opportunity
In a statement, Shields expressed his excitement about joining Versa Vascular, highlighting the promising clinical results and the potential of the AdapTR technology. He noted the device shows promise to create a superior therapy for patients with tricuspid valve disease. He also thanked his predecessor for establishing a strong foundation for the company's future success.
Investors have voiced strong support for the company's direction and new leadership. Brian R. Smith of S3 Ventures affirmed his firm's belief in Versa's vision to improve patients' lives. Dr. Louis A. Cannon of BioStar Capital praised Shields' deep structural heart expertise and industry connections as critical assets for the company.
Versa Vascular is addressing a significant unmet need in cardiovascular health, as heart valve disease affects over seven million Americans. Many patients with dysfunctional tricuspid valves are poor candidates for traditional open-heart surgery due to high procedural risks. The company's transcatheter therapy is designed to provide a viable treatment option for this underserved patient population.
With the appointment of an experienced CEO, a fortified balance sheet, and a clear clinical pathway, Versa Vascular is well-positioned for its next phase of growth. The company's focus on its innovative AdapTR device aims to transform the treatment landscape for tricuspid valve disease. This strategic momentum could soon provide a much-needed therapeutic option for patients with limited alternatives.